The long-term cardiovascular risks associated with Vigora 50 Mg are not fully understood. However, there are several hypothesized mechanisms that warrant consideration. Prolonged use of PDE5 inhibitors may lead to vascular remodeling, endothelial dysfunction, and alterations in blood pressure regulation, which could increase the risk of cardiovascular events over time.